|
US928641A
(en)
|
1908-10-09 |
1909-07-20 |
Levi E Edmunds |
Clasp for pilings.
|
|
US4957939A
(en)
|
1981-07-24 |
1990-09-18 |
Schering Aktiengesellschaft |
Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
|
|
US4472509A
(en)
|
1982-06-07 |
1984-09-18 |
Gansow Otto A |
Metal chelate conjugated monoclonal antibodies
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US5308626A
(en)
|
1985-06-28 |
1994-05-03 |
Toni N. Mariani |
Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases
|
|
US4938948A
(en)
|
1985-10-07 |
1990-07-03 |
Cetus Corporation |
Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
|
|
US4868103A
(en)
|
1986-02-19 |
1989-09-19 |
Enzo Biochem, Inc. |
Analyte detection by means of energy transfer
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
GB9022788D0
(en)
|
1990-10-19 |
1990-12-05 |
Cortecs Ltd |
Pharmaceutical formulations
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
ATE207080T1
(de)
|
1991-11-25 |
2001-11-15 |
Enzon Inc |
Multivalente antigen-bindende proteine
|
|
EP0552108B1
(en)
|
1992-01-17 |
1999-11-10 |
Lakowicz, Joseph R. |
Energy transfer phase-modulation fluoro-immunoassay
|
|
US5965132A
(en)
|
1992-03-05 |
1999-10-12 |
Board Of Regents, The University Of Texas System |
Methods and compositions for targeting the vasculature of solid tumors
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
US6096289A
(en)
|
1992-05-06 |
2000-08-01 |
Immunomedics, Inc. |
Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
US20020136725A1
(en)
|
1996-01-17 |
2002-09-26 |
Smithkline Beecham Corporation |
Antithrombotic agents
|
|
US6107090A
(en)
|
1996-05-06 |
2000-08-22 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
|
|
JP4318752B2
(ja)
|
1996-05-31 |
2009-08-26 |
ヘルス・リサーチ・インコーポレーテッド |
抗エンドグリンモノクローナル抗体および抗血管新生治療におけるその使用
|
|
US6190660B1
(en)
|
1996-05-31 |
2001-02-20 |
Health Research, Inc. |
Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
|
|
US5796097A
(en)
|
1997-03-05 |
1998-08-18 |
California Lightwave Laboratories, Inc. |
Chemical sensor and method
|
|
CA2635352C
(en)
|
1997-06-13 |
2012-09-11 |
Genentech, Inc. |
Stabilized antibody formulation
|
|
US6610293B1
(en)
|
1997-06-16 |
2003-08-26 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
|
|
EP1140840B1
(en)
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US6635677B2
(en)
|
1999-08-13 |
2003-10-21 |
Case Western Reserve University |
Methoxyamine combinations in the treatment of cancer
|
|
HUP0204475A2
(en)
|
2000-02-11 |
2003-04-28 |
Merck Patent Gmbh |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
AU2002213441B2
(en)
|
2000-10-12 |
2006-10-26 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
WO2002069232A2
(en)
|
2001-02-19 |
2002-09-06 |
Merck Patent Gmbh |
Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
|
|
WO2002072824A2
(en)
|
2001-02-20 |
2002-09-19 |
Bayer Aktiengesellschaft |
Human transient receptor potential channel protein.
|
|
US20050048512A1
(en)
|
2001-04-26 |
2005-03-03 |
Avidia Research Institute |
Combinatorial libraries of monomer domains
|
|
US20030082630A1
(en)
|
2001-04-26 |
2003-05-01 |
Maxygen, Inc. |
Combinatorial libraries of monomer domains
|
|
US20040175756A1
(en)
|
2001-04-26 |
2004-09-09 |
Avidia Research Institute |
Methods for using combinatorial libraries of monomer domains
|
|
US20050053973A1
(en)
|
2001-04-26 |
2005-03-10 |
Avidia Research Institute |
Novel proteins with targeted binding
|
|
EP1610751A4
(en)
|
2001-04-26 |
2006-05-24 |
Univ Texas |
THERAPEUTIC AGENT / LIGAND CONJUGATE COMPOSITIONS, ITS SYNTHESIS PROCESSES AND ITS APPLICATION
|
|
US20050089932A1
(en)
|
2001-04-26 |
2005-04-28 |
Avidia Research Institute |
Novel proteins with targeted binding
|
|
MXPA05000511A
(es)
|
2001-07-12 |
2005-09-30 |
Jefferson Foote |
Anticuepros super humanizados.
|
|
JP4213586B2
(ja)
|
2001-09-13 |
2009-01-21 |
株式会社抗体研究所 |
ラクダ抗体ライブラリーの作製方法
|
|
WO2003028840A2
(en)
|
2001-09-27 |
2003-04-10 |
Board Of Regents, The University Of Texas System |
Combined compositions and methods for tumor vasculature coagulation and treatment
|
|
US7115716B2
(en)
|
2001-11-19 |
2006-10-03 |
Eli Lilly And Company |
Tumor specific monoclonal antibodies
|
|
CN101721362B
(zh)
|
2002-02-14 |
2018-07-03 |
中外制药株式会社 |
包含抗体的溶液制剂
|
|
US7718776B2
(en)
|
2002-04-05 |
2010-05-18 |
Amgen Inc. |
Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
US7754884B2
(en)
|
2005-01-03 |
2010-07-13 |
Vanderbilt University |
Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging
|
|
US7097836B1
(en)
|
2002-10-23 |
2006-08-29 |
Health Research, Inc. |
Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody
|
|
US7691374B2
(en)
|
2002-10-23 |
2010-04-06 |
Health Research, Inc. |
Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody
|
|
DE10303664A1
(de)
|
2003-01-23 |
2004-08-12 |
Nemod Immuntherapie Ag |
Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
|
|
US7120987B2
(en)
|
2003-08-05 |
2006-10-17 |
Avery Dennison Corporation |
Method of making RFID device
|
|
WO2005037867A1
(en)
|
2003-10-15 |
2005-04-28 |
Pdl Biopharma, Inc. |
ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
|
|
US20050164301A1
(en)
|
2003-10-24 |
2005-07-28 |
Avidia Research Institute |
LDL receptor class A and EGF domain monomers and multimers
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
WO2006100582A1
(en)
|
2005-03-25 |
2006-09-28 |
Glycart Biotechnology Ag |
Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function
|
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
|
CN101309703A
(zh)
|
2005-09-12 |
2008-11-19 |
诺维莫尼公司 |
抗cd3抗体组合物
|
|
WO2007041643A1
(en)
|
2005-10-03 |
2007-04-12 |
University Of Tennessee Research Foundation |
Dietary calcium for reducing the production of reactive oxygen species
|
|
US8053569B2
(en)
|
2005-10-07 |
2011-11-08 |
Armagen Technologies, Inc. |
Nucleic acids encoding and methods of producing fusion proteins
|
|
CA2663243A1
(en)
|
2006-09-28 |
2008-04-03 |
Merck Serono S.A. |
Junctional adhesion molecule-c (jam-c) binding compounds and methods of their use
|
|
TW200831129A
(en)
|
2006-10-06 |
2008-08-01 |
Amgen Inc |
Stable formulations
|
|
BRPI0806414A2
(pt)
|
2007-02-01 |
2011-09-06 |
Genentech Inc |
método para tratamento de tumor
|
|
US8748379B2
(en)
|
2007-06-06 |
2014-06-10 |
Research Development Foundation |
RTEF-1 variants and the use thereof for inhibition of angiogenesis
|
|
CA2699349C
(en)
|
2007-09-14 |
2016-04-19 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted tricyclic heterocyclic compounds for use as egfr inhibitors
|
|
TWI468417B
(zh)
|
2007-11-30 |
2015-01-11 |
Genentech Inc |
抗－ｖｅｇｆ抗體
|
|
EP2235189A1
(en)
|
2008-01-14 |
2010-10-06 |
Genentech, Inc. |
Methods for inhibiting angiogenesis using egfl8 antagonists
|
|
JP2011523551A
(ja)
|
2008-05-15 |
2011-08-18 |
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル |
血管形成の調節の新規ターゲット
|
|
PT2350005E
(pt)
|
2008-08-29 |
2012-03-12 |
Bayer Pharma AG |
Polimorfo b de n-(2-aminofenil)-4-[n-(piridina-3-il)¿ metoxicarbonil-aminometil]-benzamida (ms-275)
|
|
JP2012502649A
(ja)
|
2008-09-19 |
2012-02-02 |
メディミューン，エルエルシー |
Ｃｄ１０５を対象とする標的結合剤およびその使用
|
|
US8699361B2
(en)
|
2008-09-30 |
2014-04-15 |
Qualcomm Incorporated |
Out-of-synchronization handling method and apparatus
|
|
US20100082438A1
(en)
|
2008-10-01 |
2010-04-01 |
Ronnie Jack Garmon |
Methods and systems for customer performance scoring
|
|
EP2196476A1
(en)
|
2008-12-10 |
2010-06-16 |
Novartis Ag |
Antibody formulation
|
|
AU2010221156A1
(en)
|
2009-03-06 |
2011-09-22 |
Genentech, Inc. |
Antibody formulation
|
|
US20180057602A1
(en)
|
2009-08-17 |
2018-03-01 |
Tracon Pharmaceuticals, Inc. |
Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents
|
|
US20120244147A1
(en)
|
2009-08-17 |
2012-09-27 |
Theuer Charles P |
Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents
|
|
US8221753B2
(en)
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
|
BR112012033457A2
(pt)
|
2010-07-02 |
2017-04-04 |
Medimmune Llc |
formulações de anticorpo.
|
|
JP6250533B2
(ja)
|
2011-04-20 |
2017-12-20 |
アクセレロン ファーマ インコーポレイテッドＡｃｃｅｌｅｒｏｎ Ｐｈａｒｍａ，Ｉｎｃ． |
エンドグリンポリペプチドおよびその使用
|
|
EP2739645B1
(en)
|
2011-08-01 |
2018-12-19 |
Tufts Medical Center, Inc. |
Endoglin-specific antibody for use in a method of treating heart failure and related conditions
|
|
UA115789C2
(uk)
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
|
US10214590B2
(en)
|
2013-09-20 |
2019-02-26 |
Tufts Medical Center, Inc. |
Inhibitors of endoglin activity for the treatment of fibrosis
|
|
GB201402009D0
(en)
|
2014-02-06 |
2014-03-26 |
Oncomatryx Biopharma S L |
Antibody-drug conjugates and immunotoxins
|
|
US9926375B2
(en)
|
2014-11-12 |
2018-03-27 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
|
CA2966905A1
(en)
|
2014-11-12 |
2016-05-19 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
|
WO2018067819A1
(en)
|
2016-10-06 |
2018-04-12 |
Tracon Pharmaceuticals, Inc. |
Compositions and methods for treatment of cancers
|
|
WO2018187158A1
(en)
|
2017-04-07 |
2018-10-11 |
Tracon Pharmaceuticals, Inc. |
Combination therapy of cancer with anti-endoglin antibodies and anti-programmed death receptor agents
|